7251-09-4

Basic information

• Product Name: 4-AMINO-2-METHOXY-BENZONITRILE
• Synonyms: 4-AMINO-2-METHOXY-BENZONITRILE;4-Cyano-3-Methoxyaniline;NSC 30614;Benzonitrile,4-aMino-2-Methoxy-
• CAS NO: 7251-09-4
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.16192
• Mol File: 7251-09-4.mol
• Article Data: 18

Chemical Properties

• Melting Point: 102℃
• Boiling Point: 351.2 °C at 760mmHg
• Flash Point: 166.2 °C
• Appearance: /
• Density: 1.17 g/cm³
• Vapor Pressure: 4.18E-05mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: 1.30±0.10(Predicted)
• CAS DataBase Reference: 4-AMINO-2-METHOXY-BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-2-METHOXY-BENZONITRILE(7251-09-4)
• EPA Substance Registry System: 4-AMINO-2-METHOXY-BENZONITRILE(7251-09-4)

Safety Data

• Hazardous Substances Data: 7251-09-4(Hazardous Substances Data)

Usage

General Description

4-Amino-2-methoxy-benzonitrile, also known as 2-amino-4-methoxybenzonitrile, is a chemical compound with the molecular formula C8H8N2O. It is a crystalline solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. This chemical has potential applications in the production of dyes, pigments, and agricultural chemicals. It is also used in the research and development of new drugs and materials. 4-Amino-2-methoxy-benzonitrile is considered to be a hazardous substance and should be handled with care, following proper safety precautions.

InChI:InChI=1/C8H8N2O/c1-11-8-4-7(10)3-2-6(8)5-9/h2-4H,10H2,1H3

Upstream product

• 28163-00-0 4-nitro-2-chlorobenzonitrile 
• 67608-58-6 4-cyano-3-hydroxy-aniline 
• 616-38-6 carbonic acid dimethyl ester 
• 5453-86-1 methyl 6-nitro-1,2-benzisoxazole-3-carboxylate 
• 58605-12-2 (2,4-dinitro-phenyl)-acetic acid methyl ester 
• 39835-14-8 2-hydroxy-4-nitro-benzonitrile 
• 2620-44-2 5-nitro-1,3-benzodioxole 
• 104066-80-0 N-(4-bromo-3-methoxyphenyl)acetamide 
• 588-16-9 m-methoxyacetanilide 
• 536-90-3 m-Anisidine 
• 101084-96-2 2-methoxy-4-nitrobenzonitrile 

Downstream Products

• 84954-08-5 4-cyano-3-methoxyphenyl isocyanate 
• 609785-70-8 N-tert-butoxycarbonyl-4-cyano-3-methoxyaniline 
• 1101109-32-3 2-amino-5-cyano-4-methoxybenzoic acid 
• 1072127-13-9 C₂₃H₃₂N₂O₂Si 
• 959694-12-3 (R)-4-[2,5-dioxo-4-(4-methoxyphenyl)-4-methylimidazolidin-1-yl]-2-methoxybenzonitrile 
• 1309684-50-1 (2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (4-carbamoyl-3-methoxyphenyl)amide 
• 398487-31-5 4-chloro-7-methoxyquinoline-6-carbonitrile 
• 417716-92-8 lenvatinib 
• 67608-58-6 4-cyano-3-hydroxy-aniline 
• 609785-73-1 tert-butyl 2-[benzyl(methyl)-amino]ethyl(4-cyano-3-methoxyphenyl)carbamate 

Relevant articles and documents

Preparation method of lenvatinib

The invention discloses a preparation method of lenvatinib, which comprises the following steps: by using 4-nitro-2-chlorobenzonitrile as an initial raw material, introducing nitro into molecules forelectron withdrawing, thereby greatly lowering the elect

CONDENSED HETEROCYCLIC COMPOUND

The present invention provides a fused heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I'): wherein each symbol is as defined in the specification, provided that 2-(2-((4-cyanophenyl)amino)-2-oxoethoxy)-N-(9-ethyl-9H-carbazol-3-yl)acetamide and N-(4-cyanophenyl)-N'-(9-ethyl-9H-carbazol-3-yl)-3-methylpentanediamide are excluded, or a salt thereof.

Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynamin-related protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA)

An established inhibitor ot dynamin-related protein 1 (Drp1), 3-(2,4-dichloro-5-methoxyphenyl)- 2- thioxoquinazoline-4-one (mdivi-1), was recently reported also to show potent puromycin-sensitive aminopeptidase (PSA)-inhibitory activity. Herein, we report structural development of mdivi-1 derivatives and structure-activity relationship (SAR) analysis of the synthesized compounds, as well as the structurally related PSA-specific inhibitor 3-(2,6-diethylphenyl)quinazoline-2,4-dione (PAQ-22), with the aim of identifying key structural features for inhibitory activity in order to develop selective inhibitors of Drpl, which is a potential target for treatment of Huntington's disease. Among the synthesized compounds, 3-(4-chloro3methoxyphenyl)-2-thioxoquinazoline-4-one 10g) exhibited more potent Drpl-inhibitory activity than mdivi-1 with high selectivity for Drpl over PSA.